Inotuzumab Ozogamicin and Vincristine Sulfate Liposome in Treating Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia

Conditions:   Allogeneic Hematopoietic Stem Cell Transplantation Recipient;   Blasts 5 Percent or More of Bone Marrow Nucleated Cells;   Blasts 5 Percent or More of Peripheral Blood White Cells;   CD22 Positive;   Lymphoblasts 20 Percent or More of Bone Marrow Nucleated Cells;   Lymphoblasts 20 Percent or More of Peripheral Blood White Cells;   Recurrent B Acute Lymphoblastic Leukemia;   Refractory B Acute Lymphoblastic Leukemia Interventions:   Biological: Inotuzumab Ozogamicin;   Other: Quality-of-Life Assessment;   Drug: Vincristine Sulfate Liposome Sponsors:   Roswell Park Cancer Institute;   National Cancer Institute (NCI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials